Searchable abstracts of presentations at key conferences in obesity

ob0003ou5 | An update on pharmaceutical therapy and new treatments | OU2021

The future of anti-obesity medication

Finer Nick

Newer anti-obesity medications (AOM) now offer the prospect of double-digit weight loss, and potentially clinical benefits beyond those from weight loss alone (e.g., diabetes remission, cardiovascular protection) all on a background of increasing prevalence and severity of obesity in most countries. Currently the analytical framework for evaluating efficacy has been anthropometric-centric but will need to develop as it has in other chronic disease areas to be more complication...

ob0004oc1 | Oral Communications | OU2024

Tier 3 Obesity Services in England - ongoing failure to meet need

Finer Nick , Seagar Sarah , Linda Parson , Cecilia Pyper

Provision of Tier 3 (T3) services as defined in NHS commissioning guidelines are integral to NICE obesity guidelines. Previous surveys have shown that people with obesity face a postcode lottery in accessing them. With the establishment of Integrated Care Boards (ICBs) now responsible for commissioning T3 services, we undertook a survey using Freedom of Information requests to all English ICBs in October 2023 asking for: a comprehensive outline of the T3 obesity care pathways;...